{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020569","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.339167+00:00","generated_at":"2026-06-15T06:18:52.245408+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tempest Q1 2023 net loss $7.6M ($0.55/shr); positive TPST-1120 HCC data highlighted","bullets":["Net loss $7.6M ($0.55 per share) vs $8.5M ($1.18) in Q1 2022; cash $22.9M, runway through Q2 2024.","TPST-1120 in first-line HCC: unconfirmed ORR 30% (12/40) vs 17.2% control, 74.4% relative improvement.","Confirmed ORR 17.5% (7/40) vs 10.3% control, 69.9% relative improvement; 80% TPST-1120 arm on study vs 50% control.","TPST-1495 enrolling endometrial cancer arm with pembrolizumab; TREX1 inhibitor preclinical data presented at AACR.","Expects updated TPST-1120 data from Roche; plans to report TPST-1495 data at ASCO 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020569","json":"https://secwatch.observer/filing/0000950170-23-020569.json","markdown":"https://secwatch.observer/filing/0000950170-23-020569.md","text":"https://secwatch.observer/filing/0000950170-23-020569.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023020569/0000950170-23-020569-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023020569/tpst-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:18:52.245408+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"303c11dabd6fada37a1120ae4f5d2adf71b9c53a","claim":"Tempest Therapeutics, Inc. reported quarter ended March 31, 2023 results: net income Net loss and net loss per share for the quarter ended March 31, 2023 were $7.6 million and $0.55, respectively, EPS $0.55.","evidence_excerpt":"Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class i therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023020569/0000950170-23-020569-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss and net loss per share for the quarter ended March 31, 2023 were $7.6 million and $0.55, respectively"},{"label":"EPS","value":"$0.55"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}